Biohaven Ltd BHVN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Biohaven's stock surges as treatment slows progress of neurological disorder
-
Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA)
-
Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia
-
Biohaven Reports Second Quarter 2024 Financial Results and Recent Business Developments
Trading Information
- Previous Close Price
- $51.18
- Day Range
- $50.24–51.63
- 52-Week Range
- $22.12–62.21
- Bid/Ask
- $50.23 / $51.00
- Market Cap
- $4.82 Bil
- Volume/Avg
- 705,281 / 990,763
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. Its products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 239
- Website
- https://www.biohavenpharma.com
Comparables
Valuation
|
Metric
|
BHVN
|
EXEL
|
TGTX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 17.02 | 39.71 |
Price/Book Value | 12.27 | 3.49 | 20.78 |
Price/Sales | — | 3.97 | 10.36 |
Price/Cash Flow | — | 16.25 | 27.07 |
Price/Earnings
BHVN
EXEL
TGTX
Financial Strength
|
Metric
|
BHVN
|
EXEL
|
TGTX
|
|---|---|---|---|
Quick Ratio | 2.85 | 4.05 | 2.77 |
Current Ratio | 3.27 | 4.27 | 3.58 |
Interest Coverage | — | — | 8.72 |
Quick Ratio
BHVN
EXEL
TGTX
Profitability
|
Metric
|
BHVN
|
EXEL
|
TGTX
|
|---|---|---|---|
Return on Assets (Normalized) | −141.24% | 14.82% | 40.17% |
Return on Equity (Normalized) | −189.64% | 19.05% | 94.57% |
Return on Invested Capital (Normalized) | −174.81% | 14.99% | 57.84% |
Return on Assets
BHVN
EXEL
TGTX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Hxwzgntgr | Qlrjb | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Gzsjhvvk | Xkrhxlv | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Wcgkzzjl | Knvgk | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Mtzxbhj | Zhkyld | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Hxjxghcv | Rfp | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Wsvcfwdvt | Lfft | $28.1 Bil | |||
| Moderna Inc
MRNA
| Vhmrmvsc | Fvvv | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Bdlpfnfv | Dcmnr | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Drmhvnft | Rdcdcpl | $13.4 Bil | |||
| Incyte Corp
INCY
| Rclxllwv | Rsyptwx | $12.7 Bil |
United States